EMA’s PRIME Process Could Be A Model For Tackling Pediatric Development Issues, Says Industry

16 Apr 2018
News

Vibha Sharma @ScripRegVibha vibha.sharma@informa.com

Executive Summary

The EMA can learn from its existing processes to ensure that the EU Paediatric Regulation is implemented in a way that fits more naturally with the industry's product development process and allows for improved dialogue, EFPIA has suggested.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Subjects
Pediatrics
Clinical Trials
Regulation
Regions
Europe
Industries
BioPharmaceutical

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Pediatrics Clinical Trials Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS122901

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS122901

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

EMA’s PRIME Process Could Be A Model For Tackling Pediatric Development Issues, Says Industry

News

Executive Summary

Related Content

EU Action Plan To Address Common Criticisms Of Paediatric Regulation

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert